Smyth EC, et al. Gastric cancer. Lancet. 2020;396(10251):635–48. https://doi.org/10.1016/s0140-6736(20)31288-5.

Article  CAS  PubMed  Google Scholar 

Guan WL, et al. Gastric cancer treatment: recent progress and future perspectives. J Hematol Oncol. 2023;16(1):57. https://doi.org/10.1186/s13045-023-01451-3.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bang YJ, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376(9742):687–97. https://doi.org/10.1016/s0140-6736(10)61121-x.

Article  CAS  PubMed  Google Scholar 

Ajani JA, et al. Gastric Cancer, Version 22022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2022;20(2):167–92. https://doi.org/10.6004/jnccn.2022.0008.

Article  CAS  PubMed  Google Scholar 

Blangé D, et al. Resistance mechanisms to HER2-targeted therapy in gastroesophageal adenocarcinoma: A systematic review. Cancer Treat Rev. 2022;108:102418. https://doi.org/10.1016/j.ctrv.2022.102418.

Article  CAS  PubMed  Google Scholar 

Shitara K, et al. Efficacy of trastuzumab emtansine in Japanese patients with previously treated HER2-positive locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma: A subgroup analysis of the GATSBY study. Asia Pac J Clin Oncol. 2019;16(1):5–13. https://doi.org/10.1111/ajco.13243.

Article  PubMed  Google Scholar 

Ruschoff J, et al. HER2 testing in gastric cancer: a practical approach. Mod Pathol. 2012;25(5):637–50. https://doi.org/10.1038/modpathol.2011.198.

Article  CAS  PubMed  Google Scholar 

Tokunaga M, et al. Early endpoints of a randomized phase II trial of preoperative chemotherapy with S-1/CDDP with or without trastuzumab followed by surgery for HER2-positive resectable gastric or esophagogastric junction adenocarcinoma with extensive lymph node metastasis: Japan Clinical Oncology Group study JCOG1301C (Trigger Study). Gastric Cancer. 2024;27(3):580–9. https://doi.org/10.1007/s10120-024-01467-9.

Article  CAS  PubMed  Google Scholar 

Hofheinz RD, et al. Trastuzumab in combination with 5-fluorouracil, leucovorin, oxaliplatin and docetaxel as perioperative treatment for patients with human epidermal growth factor receptor 2-positive locally advanced esophagogastric adenocarcinoma: A phase II trial of the Arbeitsgemeinschaft Internistische Onkologie Gastric Cancer Study Group. Int J Cancer. 2021;149(6):1322–31. https://doi.org/10.1002/ijc.33696.

Article  CAS  PubMed  Google Scholar 

Rivera F, et al. Perioperative trastuzumab, capecitabine and oxaliplatin in patients with HER2-positive resectable gastric or gastro-oesophageal junction adenocarcinoma: NEOHX phase II trial. Eur J Cancer. 2021;145:158–67. https://doi.org/10.1016/j.ejca.2020.12.005.

Article  CAS  PubMed  Google Scholar 

Janjigian YY, et al. First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial. Lancet Oncol. 2020;21(6):821–31. https://doi.org/10.1016/s1470-2045(20)30169-8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Janjigian YY, et al. The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer. Nature. 2021;600(7890):727–30. https://doi.org/10.1038/s41586-021-04161-3.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Janjigian YY, et al. Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial. Lancet. 2023;402(10418):2197–208. https://doi.org/10.1016/s0140-6736(23)02033-0.

Article  CAS  PubMed  Google Scholar 

Lee CK, et al. A single arm phase Ib/II trial of first-line pembrolizumab, trastuzumab and chemotherapy for advanced HER2-positive gastric cancer. Nat Commun. 2022;13(1):6002. https://doi.org/10.1038/s41467-022-33267-z.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Montagnani F, et al. Effectiveness and safety of oxaliplatin compared to cisplatin for advanced, unresectable gastric cancer: a systematic review and meta-analysis. Gastric Cancer. 2011;14(1):50–5. https://doi.org/10.1007/s10120-011-0007-7.

Article  CAS  PubMed  Google Scholar 

Kim GM, et al. A randomized phase II trial of S-1-oxaliplatin versus capecitabine-oxaliplatin in advanced gastric cancer. Eur J Cancer. 2012;48(4):518–26. https://doi.org/10.1016/j.ejca.2011.12.017.

Article  CAS  PubMed  Google Scholar 

Mori Y, et al. Phase II Prospective Study of Trastuzumab in Combination with S-1 and Oxaliplatin (SOX100) Therapy for HER2-Positive Advanced Gastric Cancer. J Gastrointest Cancer. 2022;53(4):930–8. https://doi.org/10.1007/s12029-021-00711-0.

Article  CAS  PubMed  Google Scholar 

Takahari D, et al. Multicenter phase II study of trastuzumab with S-1 plus oxaliplatin for chemotherapy-naïve, HER2-positive advanced gastric cancer. Gastric Cancer. 2019;22(6):1238–46. https://doi.org/10.1007/s10120-019-00973-5.

Article  CAS  PubMed  Google Scholar 

Yuki S, et al. Multicenter phase II study of SOX plus trastuzumab for patients with HER2(+) metastatic or recurrent gastric cancer: KSCC/HGCSG/CCOG/PerSeUS 1501B. Cancer Chemother Pharmacol. 2020;85(1):217–23. https://doi.org/10.1007/s00280-019-03991-3.

Article  CAS  PubMed  Google Scholar 

Makiyama A, et al. Randomized, Phase II Study of Trastuzumab Beyond Progression in Patients With HER2-Positive Advanced Gastric or Gastroesophageal Junction Cancer: WJOG7112G (T-ACT Study). J Clin Oncol. 2020;38(17):1919–27. https://doi.org/10.1200/jco.19.03077.

Article  CAS  PubMed  Google Scholar 

Horita Y, et al. Phase II clinical trial of second-line weekly paclitaxel plus trastuzumab for patients with HER2-positive metastatic gastric cancer. Anticancer Drugs. 2019;30(1):98–104. https://doi.org/10.1097/cad.0000000000000691.

Article  CAS  PubMed  Google Scholar 

Kawamoto Y, et al. Phase II Study of Continued Trastuzumab Plus Irinotecan in Patients with HER2-positive Gastric Cancer Previously Treated with Trastuzumab (HGCSG 1201). Oncologist. 2022;27(5):340-e374. https://doi.org/10.1093/oncolo/oyab062.

Article  PubMed  PubMed Central  Google Scholar 

Takahashi M, et al. Phase II Study of the Reuse of Trastuzumab with Docetaxel beyond Progression after First-Line Treatment in Second-Line Treatment for Unresectable, Metastatic Gastric Cancer (T-CORE1203). Tohoku J Exp Med. 2021;254(1):49–55. https://doi.org/10.1620/tjem.254.49.

Article  CAS  PubMed  Google Scholar 

Sun J, et al. From Anti-HER-2 to Anti-HER-2-CAR-T Cells: An Evolutionary Immunotherapy Approach for Gastric Cancer. J Inflamm Res. 2022;15:4061–85. https://doi.org/10.2147/jir.S368138.

Article  PubMed  PubMed Central  Google Scholar 

Zhang H, et al. Anti-HER2 scFv-CCL19-IL7 recombinant protein inhibited gastric tumor growth in vivo. Sci Rep. 2022;12(1):10461. https://doi.org/10.1038/s41598-022-14336-1.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Song Y, et al. Effective and persistent antitumor activity of HER2-directed CAR-T cells against gastric cancer cells in vitro and xenotransplanted tumors in vivo. Protein Cell. 2018;9(10):867–78. https://doi.org/10.1007/s13238-017-0384-8.

Article  CAS  PubMed  Google Scholar 

Luo F, et al. Bifunctional αHER2/CD3 RNA-engineered CART-like human T cells specifically eliminate HER2(+) gastric cancer. Cell Res. 2016;26(7):850–3. https://doi.org/10.1038/cr.2016.81.

Article  PubMed  PubMed Central